
Digital Pharma: Lilly plans social media expansion
pharmafile | September 14, 2011 | News story | Medical Communications | Digital Pharma blog, Facebook, lilly, social media, youtube
One year after launching its corporate blog Lilly is ramping up its use of social media.
Last week the company launched a new YouTube channel and tomorrow Lilly will make its official corporate debut on Facebook.
The company is obviously undeterred by August’s Facebook changes, which forced pharma companies to allow their pages to host user comments, something the industry had previously been allowed to block.
More details of Lilly’s Facebook presence will be released at tomorrow’s e-Advocacy Summit, a one-day event the company has organised in collaboration with non-profit advocacy group the Global Healthy Living Foundation.
On YouTube the company has gone for a non-branded approach with its Lilly Health Channel, which focuses on health and wellness, employee and community outreach efforts and health innovation.
“The Lilly Health Channel enables us to tell our unique stories, educate and inspire through video, like we never have before,” the company said last week in a blog post.
Lilly launched its Lilly Pad blog, and accompanying Twitter account, last September to give it more of a voice in areas such as public policy, corporate responsibility initiatives, advocacy, and the work of its employees.
Dominic Tyer is web editor for Pharmafocus and InPharm.com and the author of the Digital Pharma blog He can be contacted via email, Twitter, LinkedIn or Google+.
Related Content
NICE RECOMMENDS LILLY’S TIRZEPATIDE (MOUNJARO ®▼) FOR MANAGING OVERWEIGHT AND OBESITY IN FINAL DRAFT GUIDANCE
BASINGSTOKE, 5th December 2024 – Eli Lilly and Company announced today that the National Institute …

Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy
The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the …

Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial
Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and …






